DE69927960D1 - Epiallopregnanolon zur behandlung von krankheiten des cns - Google Patents
Epiallopregnanolon zur behandlung von krankheiten des cnsInfo
- Publication number
- DE69927960D1 DE69927960D1 DE69927960T DE69927960T DE69927960D1 DE 69927960 D1 DE69927960 D1 DE 69927960D1 DE 69927960 T DE69927960 T DE 69927960T DE 69927960 T DE69927960 T DE 69927960T DE 69927960 D1 DE69927960 D1 DE 69927960D1
- Authority
- DE
- Germany
- Prior art keywords
- epiallopregnanolone
- treatment
- cns
- diseases
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 title abstract 5
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3786998A | 1998-03-11 | 1998-03-11 | |
| US37869 | 1998-03-11 | ||
| PCT/EP1999/001496 WO1999045931A1 (en) | 1998-03-11 | 1999-03-10 | Epiallopregnanolone in the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69927960D1 true DE69927960D1 (de) | 2005-12-01 |
| DE69927960T2 DE69927960T2 (de) | 2006-07-20 |
Family
ID=21896803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69927960T Expired - Lifetime DE69927960T2 (de) | 1998-03-11 | 1999-03-10 | Epiallopregnanolon zur behandlung von krankheiten des cns |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6455516B1 (de) |
| EP (1) | EP1063999B1 (de) |
| JP (1) | JP3877961B2 (de) |
| CN (1) | CN1270718C (de) |
| AT (1) | ATE307592T1 (de) |
| AU (1) | AU756001B2 (de) |
| CA (1) | CA2321728C (de) |
| DE (1) | DE69927960T2 (de) |
| WO (1) | WO1999045931A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| DK1812009T3 (da) * | 2004-11-18 | 2013-08-05 | Umecrine Ab | GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser |
| DE102006003509A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Kontrazeptivum |
| DE102006003508A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Arzneimittel umfassend eine Hormonkombination |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| CA2664126C (en) | 2006-11-21 | 2014-04-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| US8969329B2 (en) | 2007-06-11 | 2015-03-03 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function |
| US20100204192A1 (en) | 2007-06-11 | 2010-08-12 | University Of Sourthern California | Agents, compositions and methods for enhancing neurological function |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| CA2786330C (en) | 2010-01-14 | 2013-11-19 | Umecrine Mood Ab | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| EP3170501B1 (de) * | 2011-05-20 | 2020-07-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonisten des cb1-rezeptors |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| IL298436B2 (en) | 2012-01-23 | 2024-07-01 | Sage Therapeutics Inc | Pharmaceutical preparations that include allopregnanolone |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| AU2013305767B2 (en) | 2012-08-21 | 2018-05-24 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| PE20151557A1 (es) | 2012-11-28 | 2015-11-18 | Inst Nat Sante Rech Med | Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona |
| US20150313915A1 (en) * | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| BR112016017620A2 (pt) | 2014-01-29 | 2017-08-08 | Umecrine Cognition Ab | Composto esteroidal para uso no tratamento da encefalopatia hepática |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10774108B2 (en) * | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| AR103384A1 (es) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA |
| SG11201807785VA (en) | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| KR102552425B1 (ko) * | 2017-01-09 | 2023-07-06 | 아사리나 파마 아베 | 주사가능한 현탁액 |
| WO2018147791A1 (en) * | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| CA3049954A1 (en) * | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |
| US20210228596A1 (en) * | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| KR20200140832A (ko) | 2018-04-05 | 2020-12-16 | 아사리나 파마 에이피에스 | 물질 금단 장애를 치료하기 위한 gaba-a 길항제 |
| KR20240050372A (ko) | 2021-09-14 | 2024-04-18 | 난징 미노바 파마슈티컬 컴퍼니, 리미티드 | 수용성 알로프레그나놀론 유도체 및 이의 제조 방법과 용도 |
| WO2023083978A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
| WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
| WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| AU7569194A (en) * | 1993-08-20 | 1995-03-21 | Meyer B. Jackson | Method for regulating neuropeptide hormone secretion |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| PT808325E (pt) * | 1994-11-23 | 2001-06-29 | Cocensys Inc | Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba |
| EP0981349B1 (de) * | 1997-05-02 | 2002-11-06 | Wyeth | 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten |
-
1999
- 1999-03-10 DE DE69927960T patent/DE69927960T2/de not_active Expired - Lifetime
- 1999-03-10 EP EP99914491A patent/EP1063999B1/de not_active Expired - Lifetime
- 1999-03-10 CN CNB998060283A patent/CN1270718C/zh not_active Expired - Fee Related
- 1999-03-10 AU AU33292/99A patent/AU756001B2/en not_active Ceased
- 1999-03-10 AT AT99914491T patent/ATE307592T1/de not_active IP Right Cessation
- 1999-03-10 WO PCT/EP1999/001496 patent/WO1999045931A1/en active IP Right Grant
- 1999-03-10 CA CA002321728A patent/CA2321728C/en not_active Expired - Fee Related
- 1999-03-10 JP JP2000535346A patent/JP3877961B2/ja not_active Expired - Fee Related
- 1999-03-11 US US09/266,035 patent/US6455516B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270718C (zh) | 2006-08-23 |
| JP3877961B2 (ja) | 2007-02-07 |
| ATE307592T1 (de) | 2005-11-15 |
| CA2321728A1 (en) | 1999-09-16 |
| AU3329299A (en) | 1999-09-27 |
| US6455516B1 (en) | 2002-09-24 |
| CN1300219A (zh) | 2001-06-20 |
| EP1063999B1 (de) | 2005-10-26 |
| AU756001B2 (en) | 2003-01-02 |
| DE69927960T2 (de) | 2006-07-20 |
| WO1999045931A1 (en) | 1999-09-16 |
| CA2321728C (en) | 2008-12-09 |
| EP1063999A1 (de) | 2001-01-03 |
| JP2002506034A (ja) | 2002-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE307592T1 (de) | Epiallopregnanolon zur behandlung von krankheiten des cns | |
| DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| NO20030845D0 (no) | Utvalgte fusjonerte pyrrolokarbazoler | |
| ATE350364T1 (de) | Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen | |
| ATE269866T1 (de) | Intranasale zubereitungen zur behandlung sexueller störungen | |
| ATE311371T1 (de) | Nicht-peptide inhibitoren von vla-4 abhängiger zellbindung für die behandlung von entzündungen, autoimmune krankheiten und atemstörungen | |
| HUP0003852A2 (hu) | Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására | |
| DE59810761D1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
| DE69534908D1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| DE69913548D1 (de) | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen | |
| DE60139466D1 (de) | Behandlung von diabetes | |
| DE69523654D1 (de) | Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| TR200003356T2 (tr) | Kabergolin ve pramipeksol: yeni kullanım biçimleri ve birlikte kullanılmaları. | |
| DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
| HUP0001644A2 (hu) | Eljárás kitinázok előállítására | |
| HUP0100611A2 (hu) | Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére | |
| NO990450D0 (no) | Behandling av sinnslidelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: UMECRINE MOOD AB, STOCKHOLM, SE |